Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?

被引：2

作者：

Forni, Gian Luca ^{[1
]}

Kattamis, Antonis ^{[2
]}

Kuo, Kevin H. M. ^{[3
]}

Maggio, Aurelio ^{[4
]}

Sheth, Sujit ^{[5
]}

Taher, Ali T. ^{[6
]}

Viprakasit, Vip ^{[7
,8
]}

机构：

[1] ForAnemia Fdn, Via Garibaldi 7,3C, I-16124 Genoa, Italy

[2] Natl & Kapodistrian Univ Athens, Dept Pediat 1, Athens, Greece

[3] Univ Toronto, Div Hematol, Toronto, ON, Canada

[4] AOOR Villa Sofia V Cervello, Campus Haematol Franco & Piera Cutino, Palermo, Italy

[5] Weill Cornell Med, Dept Pediat, Div Hematol & Oncol, New York, NY USA

[6] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon

[7] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Pediat, Bangkok, Thailand

[8] Mahidol Univ, Siriraj Hosp, Fac Med, Thalassemia Ctr, Bangkok, Thailand

来源：

PEDIATRIC BLOOD & CANCER | 2024年 / 71卷 / 08期

关键词：

ferritin; heart; iron chelation; iron overload; liver; thalassemia; PEDIATRIC-PATIENTS; OPEN-LABEL; DEFERASIROX; EFFICACY; SAFETY; DEFERIPRONE; DESFERRIOXAMINE; TOLERABILITY; MULTICENTER; OVERLOAD;

D O I：

10.1002/pbc.31035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this review, we provide a summary of evidence on iron overload in young children with transfusion-dependent beta-thalassemia (TDT) and explore the ideal timing for intervention. Key data from clinical trials and observational studies of the three available iron chelators deferoxamine, deferiprone, and deferasirox are also evaluated for inclusion of subsets of young children, especially those less than 6 years of age. Evidence on the efficacy and safety of iron chelation therapy for children >= 2 years of age with transfusional iron overload is widely available. New data exploring the risks and benefits of early-start iron chelation in younger patients with minimal iron overload are also emerging.

引用

页数：7

共 50 条

[31] Occult Kidney Dysfunction in Children With Transfusion-Dependent Thalassemia [J].

Zikre, Nurwahida Mohd ;

Muhamad, Nor A. ;

Eng, Caroline S. Y. ;

Zailanalhuddin, Nur E. ;

Lai, Charles D. ;

Foo, Jen C. ;

Yap, Suet L. ;

Ariffin, Hany ;

Abu Bakar, Karmila .

FRONTIERS IN PEDIATRICS, 2021, 9

[32] Efficacy and Safety of a Dispersible Tablet of GPO-Deferasirox Monotherapy among Children with Transfusion-Dependent Thalassemia and Iron Overload [J].

Chuansumrit, Ampaiwan ;

Songdej, Duantida ;

Sirachainan, Nongnuch ;

Kadegasem, Praguywan ;

Saisawat, Pawaree ;

Sungkarat, Witaya ;

Kempka, Ketsuda ;

Tungbubpha, Noppawan .

HEMOGLOBIN, 2024, 48 (01) :47-55

[33] Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes [J].

Kontoghiorghe, Christina N. ;

Kontoghiorghes, George J. .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 :465-481

[34] Subcutaneous iron chelation therapy, oral iron chelation therapy, or both in patients with thalassemia? [J].

Babrs, Gihan M. ;

Abd El-Hakeem, Mohammed A. .

EGYPTIAN JOURNAL OF HAEMATOLOGY, 2013, 38 (02) :51-55

[35] A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 μg/L [J].

Scaramellini, Natalia ;

Consonni, Dario ;

Cassinerio, Elena ;

Arighi, Carola ;

Marcon, Alessia ;

Graziadei, Giovanna ;

Cappellini, Maria Domenica ;

Motta, Irene .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (09) :E230-E232

[36] Physical growth in children with transfusion-dependent thalassemia [J].

Pemde, Harish K. ;

Chandra, Jagdish ;

Gupta, Divya ;

Singh, Varinder ;

Sharma, Rajni ;

Dutta, A. K. .

PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2011, 2 :13-19

[37] Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia [J].

Thompson, A. A. ;

Walters, M. C. ;

Kwiatkowski, J. ;

Rasko, J. E. J. ;

Ribeil, J. -A. ;

Hongeng, S. ;

Magrin, E. ;

Schiller, G. J. ;

Payen, E. ;

Semeraro, M. ;

Moshous, D. ;

Lefrere, F. ;

Puy, H. ;

Bourget, P. ;

Magnani, A. ;

Caccavelli, L. ;

Diana, J. -S. ;

Suarez, F. ;

Monpoux, F. ;

Brousse, V. ;

Poirot, C. ;

Brouzes, C. ;

Meritet, J. -F. ;

Pondarre, C. ;

Beuzard, Y. ;

Chretien, S. ;

Lefebvre, T. ;

Teachey, D. T. ;

Anurathapan, U. ;

Ho, P. J. ;

von Kalle, C. ;

Kletzel, M. ;

Vichinsky, E. ;

Soni, S. ;

Veres, G. ;

Negre, O. ;

Ross, R. W. ;

Davidson, D. ;

Petrusich, A. ;

Sandler, L. ;

Asmal, M. ;

Hermine, O. ;

De Montalembert, M. ;

Hacein-Bey-Abina, S. ;

Blanche, S. ;

Leboulch, P. ;

Cavazzana, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (16) :1479-1493

[38] Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias [J].

Viprakasit, Vip ;

Gattermann, Norbert ;

Lee, Jong Wook ;

Porter, John B. ;

Taher, Ali T. ;

Habr, Dany ;

Martin, Nicolas ;

Domokos, Gabor ;

Cappellini, Maria Domenica .

BLOOD TRANSFUSION, 2013, 11 (01) :108-122

[39] The challenges of iron chelation therapy in thalassemia: how do we overcome them? [J].

Wang, Lauren E. ;

Muttar, Sara ;

Badawy, Sherif M. .

EXPERT REVIEW OF HEMATOLOGY, 2025, 18 (05) :351-357

[40] Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia [J].

Taher, Ali T. ;

Temraz, Sally ;

Cappellini, M. Domenica .

EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) :495-509

← 1 2 3 4 5 →